Alnylam Pharmaceuticals, Inc.
Compositions and Methods for Inhibiting Expression of Transthyretin
Last updated:
Abstract:
The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and methods of using the dsRNA to inhibit expression of TTR.
Status:
Application
Type:
Utility
Filling date:
14 Feb 2019
Issue date:
10 Oct 2019